Skip to content
Krypton AI
Client portal
Demo

Book 30 minutes with us.

We prepare a first read on your company: your story, the funds that own your peers, and a short briefing. A person reviews it before we meet.

Prefer email? contact@kryptonai.io

Nature's Sunshine Products, Inc.

Ticker
NATR
Sector
Nutritional supplements
Dated
19 September 2026
Stance
BUY (initiated)

Priced for a broken direct seller at a one-year low. China is 8.5% of sales, gross margin is at a four-year high, and net cash is 27.2% of the market value.

Price (29 Sep 26)
$12.76
Price target (12m)
$14.80
Scenario value*
$14.91
Bear / Base / Bull
$10.48 / $14.84 / $19.49
Market cap
$224.6M
Enterprise value
$163.5M
Free float
71.5% of S/O
Avg daily vol, 3m
167k / $2.8M
Short interest
6.4% float, +2.1pt
Institutional own.
66.9%
Largest holder
Wynnefield, 14.1%
Insider and board
3.4%

*Probability-weighted, 25/50/25, over 12 to 24 months. Price target is the base case, rounded to the nearest ten cents.

The thesis

  1. China is 8.5% of sales, and because NATR never reports it, the market discounts the whole company. Solving from management's August growth rates puts China at roughly $41M of sales.
  2. The break in China looks like execution, not demand. Growth above 35% for three quarters turned to a 20% decline in one, after an Autoship push and the December buy-out of two Chinese joint ventures.
  3. The underlying business is at a four-year high while the stock is at a one-year low. Gross margin reached 73.7% in the June quarter, and adjusted EBITDA rose 21.7% to $49.4M in FY2025.
  4. Net cash and no debt maturities put a floor under the shares. Net cash of $61.1M after leases is 27.2% of the market value, against a bear case of $10.48 and a target of $14.80.

Read the whole thing

The business, the market, the financials, the valuation with its scenarios, the risks and the catalysts. A PDF of 6 pages, 672 KB, sent to you, free.

Nature's Sunshine Products, Inc.

The full report, free. We send it as a PDF attachment, and we use the address for new research and nothing else.

Independent research. This is not investment advice and is not a recommendation to buy or sell any security. Please consult an accredited financial adviser before making any decision.

Comments

No comments yet.

Comments are read before they appear.